Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00559299 · ClinicalTrials.gov registry record · Phase 1
Patient Tolerability Study of GSK163090
A Phase 1 study of Depressive Disorder, Major and Major Depressive Disorder (MDD), sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00559299 is a Phase 1 study of Depressive Disorder, Major and Major Depressive Disorder (MDD) that has completed, run by GlaxoSmithKline. The registered enrollment target is 20 participants, below the 242-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00559299, a Phase 1 study of Depressive Disorder, Major and Major Depressive Disorder (MDD), has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and tolerability of a new drug, GSK163090, which is being developed for the treatment of depression and anxiety disorders.
Conditions Studied
Interventions
- DRUG GSK163090
Study Locations (1)
Kansas
- GSK Investigational Site - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00559299
The ClinicalTrials.gov registry entry for NCT00559299 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (92% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Depressive Disorder, Major appearing as the primary indexed condition, and to 1 intervention - of which GSK163090 is the first listed.
NCT00559299 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT00559299 about?
NCT00559299 is a clinical study titled "Patient Tolerability Study of GSK163090". The purpose of this study is to determine the safety and tolerability of a new drug, GSK163090, which is being developed for the treatment of depression and anxiety disorders.
What is the current status of trial NCT00559299?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2007-11. Estimated completion is 2008-06.
What conditions does trial NCT00559299 study?
This clinical trial studies the following conditions: Depressive Disorder, Major, Major Depressive Disorder (MDD).
What interventions are being tested in trial NCT00559299?
The interventions under investigation include: GSK163090 (DRUG).
Who is sponsoring clinical trial NCT00559299?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00559299 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
RECRUITING · Phase 1
-
Altering Default Mode Network Activity With Transcranial Focused Ultrasound to Reduce Depressive Symptoms
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Effect of Food on LY2216684
COMPLETED · Phase 1
-
A Study of LY2216684 in Participants With Impaired Hepatic Function
COMPLETED · Phase 1
-
A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects
COMPLETED · Phase 1
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.